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Is the Bottleneck Cracked?
Since the development of molecular diagnosis of mtDNA
disease, there has been increasing pressure on clinical
geneticists for genetic counseling of this uniquely difficult
group. However, these advances have revolutionized nei-
ther prognostication nor prenatal diagnosis of mito-
chondrial diseases. This inability to predict risk of af-
fected offspring in mtDNA diseases is largely due to the
uniparental inheritance of multiple copies of mtDNA.
Recently, however, the prospects for prenatal diagnosis
of mtDNA diseases have taken a turn for the better. Until
now, the unique segregation of mtDNA mutations and
the current state of knowledge have made prenatal di-
agnosis risky in these diseases: Is the mtDNA in a cho-
rionic villus sampling (CVS) truly representative of the
fetus? How closely would the level of mtDNA mutant
in either CVS or fetus relate to prognosis? Recent data
derived from a mouse model and direct evidence from
human oocytes are helping to answer these questions.
The Problem
Despite major advances in our understanding of the
mutations and pathogenesis of mtDNA disease, genetic
counseling is at best imprecise, and prenatal diagnosis
is risky. The late Anita Harding was a reluctant pioneer
in this field (A. E. Harding, personal communication).
A woman in the original NARP (neurigenic weakness,
ataxia, and retinitis pigmentosa, associated with a point
mutation at bp 8993) family requested CVS in two preg-
nancies (Harding et al. 1992). In both cases, analysis of
mtDNA indicated that the dose of 8993 mutant mtDNA
in the CVS was 195%. Since this suggested that the fetus
would be severely affected, both the pregnancies were
terminated. Similarly, prenatal diagnosis and termina-
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tion of a fetus at high risk of NARP has also been per-
formed once in the United States (Bartley et al. 1996).
However, until now, many clinical geneticists would feel
that the uncertainties are too great to offer prenatal
diagnosis.
Every nucleated cell contains thousands of copies of
mtDNA, and it is widely held that, in normal individuals,
these mtDNAs are substantially identical (homo-
plasmic). mtDNA is maternally inherited. When a point
mutation arises, there may be complete switching to the
new mtDNA variant, within a single generation (Haus-
wirth and Laipis 1982, 1985). Because oocytes contain
∼100,000 mtDNAs and yet the mutation presumably
occurs once, it appears that only a small number of
mtDNAs ultimately populate the organism. This sug-
gests that there is first a restriction in the numbers of
mtDNA to be transmitted, followed by amplification, or
a so-called genetic bottleneck. Switching, when it occurs,
is probably incomplete more often than it is complete,
generating individuals who are heteroplasmic (i.e., who
have more than one mtDNA type). Heteroplasmy is also
a feature of mtDNA disease in which homoplasmy for
severe pathogenic mutants may be lethal. Again, large
differences in the proportions of variant mtDNAs be-
tween offspring suggest that a restriction/amplification
event has occurred at some stage. Further accumulation
of mtDNA mutants in postmitotic tissues may underlie
the progressive nature of mtDNA disease. Hence, in ad-
dition to the mitochondrial bottleneck during oogenesis,
segregation of mutants in developing tissues could con-
tribute to variation in the level of mutant mtDNA be-
tween offspring. Figure 1 illustrates how variation in the
level of mutant mtDNA might be generated in children
by alternative combinations of bottleneck and postcon-
ception segregation of mutant mtDNAs. It demonstrates
that the relative importance of bottleneck and segrega-
tion of mtDNA after fertilization are critical to the feas-
ibility of prenatal diagnosis of mtDNA diseases. If the
bottleneck is wide and has little effect, so that segre-
gation of mutants is the major source of variation (fig.
1, left panel), then CVS remains problematic. If, how-
ever, a bottleneck during oogenesis causes most of the
variation (fig. 1, right panel), then sampling either prod-
ucts of conception or oocytes will be representative of
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Figure 1 Timing and magnitude of the bottleneck, which are important for prenatal diagnosis of mtDNA diseases. This diagram illustrates
two different scenarios in which variation between generations arises either mainly by segregation during development, with a wide bottleneck
during oogenesis (left panel), or mainly by narrow bottleneck with minimal effect of segregation prenatally (right panel). If the bottleneck has
little effect, and if segregation of mutants is the major source of the variation (left panel), then CVS remains problematic; if, however, a bottleneck
during oogenesis causes most of the variation (right panel), then sampling either products of conception or oocytes will be representative of
the dose of mutant mtDNA to be transmitted.
the dose of mutant mtDNA to be transmitted. Indeed,
preimplantation diagnosis, as well as CVS, might be pos-
sible. Furthermore, sampling oocytes (e.g., after diag-
nostic superovulation) might be useful in any effort to
advise individual women about the likelihood of bearing
an unaffected fetus, which may have been low in the
case of Harding’s patient (Harding et al. 1992). The two
alternatives illustrated in the figure are extremes. The
true position for transmission of most mtDNA muta-
tions may lie somewhere between. New data are clari-
fying the uncertainties about the size and timing of this
bottleneck, which have been a major impediment to ge-
netic counseling.
Evidence for a Bottleneck in Oogenesis
The limited data gathered so far suggest that a sig-
nificant bottleneck has occurred by the time that oocytes
are mature and that there is little segregation between
fertilization and birth. These data appeared in important
studies directly investigating mtDNA in gametes in mice
and humans.
Three groups have recently constructed heteroplasmic
mouse models of mtDNA segregation, by introducing
donor cytoplasm into a fertilized recipient egg, obtaining
mice with 5%–80% (Laipis 1996), 0%–30% (Jenuth et
al. 1996), and 16%–100% (Meirelles and Smith 1997)
donor mtDNA in the resulting mouse lines. Two groups
investigated the variance of the proportions of donor
mtDNA at different developmental stages. Jenuth et al.
(1996) found that most of the difference, in the level of
mutant mtDNA, between mother and offspring was gen-
erated while primordial germ cells progressed to primary
oocytes, in their mouse model. These data suggest that
a major component of the mtDNA bottleneck has oc-
curred by the time when oocytes are mature. We showed
that individual human oocytes can be heteroplasmic for
length variants in a homopolymeric C tract in the major
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noncoding region of mtDNA. Tissues from normal in-
dividuals possessed one major length variant (195%),
but there was no difference, in the pattern of the length
variants, among somatic tissues in any control individ-
ual, when bulk samples were taken. In two normal con-
trols, the major length variants differed among oocytes
from the same donor, suggesting that segregation of
founder mtDNA molecules had occurred by the time
when oocytes were mature (Marchington et al. 1997).
Blok et al. (1997) identified almost complete segregation
of mutant and wild-type mtDNA during oogenesis in a
family carrying the pathogenic NARP mutation at po-
sition 8993. They found that 7/8 oocytes from a patient
with the 8993 mutation were almost homoplasmic for
mutant mtDNA and that 1/8 oocytes was homoplasmic
for wild-type mtDNA. These studies suggest that amajor
bottleneck occurs during oogenesis.
Although it is not possible to investigate developing
human fetuses longitudinally, the mouse models sug-
gested that mtDNA variants remain relatively evenly dis-
tributed throughout developing fetal tissues (Jenuth et
al. 1996, 1997). Furthermore, the limited data from
studies on human fetuses with pathogenic mtDNA mu-
tations also suggest that mutant mtDNAs do not seg-
regate much during embryogenesis (Harding et al. 1992;
Suomalainen et al. 1993; Matthews et al. 1994)—if so,
then the process shown in the right-hand panel of figure
1 is the nearest to reality. However, this model would
be an oversimplification if there were significant differ-
ences either between the behaviors of different patho-
genic mutations or between pathogenic mutants and
neutral variants in the developing embryo. There is good
evidence for nonrandom segregation of mtDNA post-
natally, both in mouse models (Jenuth et al. 1997) and
in studies of pathogenic human mtDNA mutants in pa-
tients (Larsson et al. 1990; Poulton and Morten 1993;
Poulton et al. 1995; Weber et al. 1997). Furthermore,
several studies of pathogenic mtDNA mutants in cell
culture suggest that segregation of mutant and wild-type
mtDNA may occur (Hayashi et al. 1991; Yoneda et al.
1992; Dunbar et al. 1995; Holt et al. 1997), perhaps
resulting from factors such as impaired mitochondrial
function, replicative advantage to mutant mtDNA
(Yoneda et al. 1992; Holt et al. 1997), and differences
in nuclear background (Dunbar et al. 1995; Holt et al.
1997).
Models Describing the Mitochondrial Bottleneck
Can we use this information to better predict trans-
mission from the mutant load in the mother and in her
previous offspring? The equations that have generally
been used to estimate mitochondrial bottleneck size are
essentially the standard Wright equations for population
drift (Howell et al. 1992). These require an accurate
estimate of the variance Vn in the offspring, which is
rarely available in the British families that we counsel.
The difficulty of calculating Vn makes its use impractical
in clinical genetics. In addition, most authors have set
the number of generations, g, at 15, in an attempt to
take the cell divisions of oogenesis into account (“re-
peated selection”).
In contrast, we have used a “single-selection” model
(Bendall et al. 1996) to infer the size of the intergener-
ational bottleneck n, assuming that it represents a one-
time sampling of a small number of mtDNAs from a
large pool. In this approach, Bayes’s theorem is used to
evaluate the posterior probability of n, given the ob-
served proportions of the heteroplasmic variants in
ovary/blood and oocytes, as well as the estimated ex-
perimental error in these proportions. This method is
able to estimate a bottleneck size on the basis of the
proportion of mutant mtDNAs in a single mother-child
pair and is able to make good estimates when these differ,
but it is not able to do so when they are similar (since
the confidence intervals then become very wide).
Which is most applicable for predicting transmission,
the single- or the repeated-selection model? Although,
superficially at least, the repeated-selection model ap-
pears to represent the physiologymore closely, the single-
selection model appears to be more appropriate to the
data available from small families. The repeated-selec-
tion model assumes that the variance in genotypic ratios
of the progeny or developing oocytes is caused by an
identical sampling event that occurs during each of the
15 or so cell divisions during oogenesis. This assumption
may not be justified. Most of the 50-fold expansion of
mtDNA that is seen as the primordial germ cells develop
into mature oocytes (Chen et al. 1995) occurs after the
final cell division of oogenesis. This expansion might be
explained by four of five rounds of replication occurring
in all mtDNAs. However, data from Xenopus oogenesis
(Tourte et al. 1984) and from studies in cultured human
somatic cells (Davis and Clayton 1996) suggest that a
small subpopulation of mtDNAs may undergo numer-
ous rounds of replication, to effect this expansion. If this
applies to human oogenesis as well, the single-selection
model would appear to be more suitable than the re-
peated-selection model. In the absence of a more accu-
rate model, what is the size of the bottleneck in the
published data cited above, and which of the alternative
models generates the best fit to the distribution of het-
eroplasmic offspring?
Jenuth et al. (1996) used their heteroplasmic mouse
model of mtDNA segregation in the female germ line
(see above) to demonstrate that a major component of
the mtDNA bottleneck has occurred by the time when
oocytes are mature. Using a repeated-selection model,
they estimated that the number of segregating units was
∼200, but this falls to 6–60 (median 13) when a single
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Figure 2 Fitting the repeated- and single-selection models to the
data on mtDNA rearrangements: idealized plots for patient 1, for
predicted percentage of mutant mtDNA in offspring, when 21% mu-
tant mtDNA is detected in ovary, for repeated sampling (g  15; n 
135; upper panel) and single selection (g1; n 8; lower panel). Both
models fit the observed distribution reasonably well (D. R. Marching-
ton and J. Poulton, unpublished data).
selection, rather than 15 selections, is used in the same
equation.
We have recently applied the single-selection model to
our study of length variants in mature oocytes from nor-
mal controls (Marchington et al. 1997) and have esti-
mated that the bottleneck size is one to five segregating
units (which could represent one to five mitochondria
or mtDNAs). We have also examined oocytes from a
patient with Kearn-Sayre syndrome caused by mtDNA
rearrangements (D. R. Marchington and J. Poulton, un-
published data). Significant levels of rearranged mtDNA
were detectable in the majority of the patient’s oocytes,
by means of multiplex PCR, with wide variation, in the
levels of mutant and wild-type molecules, between in-
dividual oocytes. Length-variation polymorphisms in the
D310 tract allowed us to identify founder subpopula-
tions of mtDNAs in this patient’s oocytes. Using a single-
selection model, these respective methods generated
most likely bottleneck sizes (n) of 1–31 (mode 8; median
9) and 6–11 in mutant and wild-type molecules. Using
single selection in the Wright equation, for the data on
the mtDNA rearrangements, we obtained a bottleneck
size of 9; using a repeated-selection model we obtained
a bottleneck size of 135 (D. R. Marchington and J. Poul-
ton, unpublished data). This range overlaps with but is
slightly lower than the data from mouse, suggesting that
the apparent disagreement between the conclusions of
these studies results more from the mathematical model
used than from the different species studied.
Blok et al. (1997) found that 7/8 oocytes from a pa-
tient with the 8993 mutation were almost homoplasmic
for mutant mtDNA and that 1/8 was homoplasmic for
wild-type mtDNA. Using a repeated-selection model,
they estimated a bottleneck size 120. However, under
both a single-selection model and the assumption that
their oocytes are virtually homoplasmic, the most likely
bottleneck size falls to 1. This estimate is smaller than
the one derived from our data on both controls and
patients with mtDNA rearrangements. Previous authors
who studied pedigrees with this mutation have noted
that they were distinctive in rapid segregation to high
levels of mutant mtDNA. It is possible that this is a result
of nonrandom segregation of mtDNA, as discussed
above. If so, the 8993 mutation may be unusual, because
the nonrandom segregation appears to become signifi-
cant in utero—that is, at a developmental stage earlier
than that characterizing many of the other point
mutations.
Predicting the Risk of Transmission
Can these data be applied to individual families? We
suggest that these recent advances can be applied to the
clinical dilemmas in two ways: in assessment of clinical
risk and in a limited development of prenatal diagnosis.
Clearly, sufficient data are rarely, if ever, available for
calculating the bottleneck size by means of the repeated-
selection model. Similarly, it will usually be necessary to
estimate rather than measure the level of mutant in ovary
or oocytes. With these limitations in mind, we have tried
fitting these predictions to observed transmissions in the
following two examples. First, figure 2 illustrates the
probability distributions predicted by the repeated-se-
lection and the single-selection models for our patient
with rearrangements discussed above (when bottleneck
sizes of 135 and 9, respectively, are used) (Marchington
et al. 1997; D. R. Marchington, V. A. Macaulay, G. M.
Hartshorne, D. Barlow, and J. Poulton, unpublished
data). The shapes of these two curves are similar, and
both fit the observed distribution reasonably well. We
conclude that, for practical purposes, either could have
been used to advise the patient about the expected level
of mutant mtDNA in her offspring at birth. Our igno-
rance both of how this could segregate postnatally and
of the relationship between the dose of mutant mtDNA
and the phenotype would, of course, limit its usefulness.
For our second example (fig. 3), we have used the family
reported by Larsson et al. (1992), because the level of
the 8344 mutant (associated with myoclonic epilepsy
and ragged red fiber [MERRF] syndrome; see Chomyn
1998 [in this issue]) generally exhibits less variation be-
tween tissues than is seen among some of the other, more
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Figure 3 Fitting a single-selection model to data on an mtDNA
point mutation. Predictions from data (Larsson et al. 1992) on a family
with the MERRF mutation. Top row, Percent of mutant mtDNA in
blood in the mother. Second row, Predicted probability of percent of
mutant mtDNA in offspring, with a single-selection model and n 
3. Third row, Predicted probablity of percent of mutant mtDNA, with
a single-selection model and n  8. Fourth row, Observed percent of
mutant mtDNA in offspring, Bottom row, Percent of mutant mtDNA
in offspring, including unaffected offspring (unblackened bars), whose
percentages of mutant mtDNA were estimated on the basis of values
in the literature (Hammans et al. 1993). This estimate was necessary
because empirical values were not available for all offspring. We sug-
gest that the predictions fit the observations sufficiently well for clinical
use in selected families.
common mtDNA mutations; hence, the level of mutant
mtDNA in blood may reflect that in ovary. We have used
a single-selection model and bottleneck sizes of 3 (a cal-
culation that could readily be done in the clinic) and 8.
In figure 3, the proportions of mutant mtDNA in the
observed offspring are represented by blackened bars.
Since the level of mutant mtDNA was not measured in
all of the unaffected offspring, an estimate has been
made for these missing values, on the basis of other data
(fig. 3, unblackened bars). In 5/6 cases, the probability
predictions for both n 3 and n 8 fit the observations
reasonably well. Since there is a reasonable correlation
between level of mutant mtDNA and severity of symp-
toms in this particular syndrome, we suggest that, in
families with the MERRF mutation, this information
could be usefully conveyed to informed patients.
We suggest that, once more data have been collected,
such estimations will become usable in the medium term;
reasonable fits may be more useful to patients than is
the quality of information currently issued. Two pieces
of information would be important for these calcula-
tions: the mean level of mutant mtDNA in oocytes and
the bottleneck size. Although it may be reasonable to
use blood levels of mutant mtDNA to estimate the level
of mutant mtDNA in ovary in patients with theMERRF
mutation, variable tissue distribution of mutant mt-
DNAs excludes this means of estimation in patients with
either rearrangements or the 3243 mutation. A better
estimate might be reached, in selected cases, by collecting
the oocytes, which could be obtained after superovu-
lation of affected women and estimating the level of
mutant mtDNA in the individual oocytes (Blok et al.
1997). Collecting sufficient oocytes would enable as-
sessment of the risk of transmission, without the need
to estimate the bottleneck size. However, estimates of
bottleneck size that are obtained from such studies and
from large pedigrees will be critically important in es-
tablishing whether the size of n is specific to the char-
acteristics of individual pathogenic mutations or to in-
dividual mothers. Second, these new data have
implications for prenatal diagnosis. A major component
of the variance between individuals seems to arise by
the time when oocytes are mature, in all the cases studied
so far. If so, prenatal diagnosis by sampling the embryo
prior to implantation would seem a logical strategy, al-
though it would not be one that is readily available in
many places. The success of CVS in identifying the fe-
tuses that are probably at high risk for developingNARP
is encouraging, but it may be a consequence of the dis-
tinctive qualities of the 8993 mutation and, therefore,
be less applicable to other mutations. Although most
clinicians will feel that CVS is not yet widely applicable
to mtDNA disease, there is clearly an urgent need to
collect the human data needed to complete the picture.
This includes quantitation of the mutant-mtDNA level
in any products of conception that become available and
documentation of the predictions made and of the out-
come for families counseled.
In conclusion, new data are clarifying the uncertainties
about the size and timing of this bottleneck, which have
been a major impediment to genetic counseling. We an-
ticipate that the mechanisms and dynamics of the bot-
tleneck will be cracked during the next few years, pro-
vided that there is a concerted international effort
toward collecting the information required. The use of
donor cytoplasm (Cohen et al. 1997), which is now tech-
nically feasible and could theoretically be used to cir-
cumvent these difficulties, is unlikely to gain ethical ap-
proval in many countries.
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